Teladoc Health Valuation
Is TDOC * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TDOC * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TDOC * (MX$221.41) is trading below our estimate of fair value (MX$493.46)
Significantly Below Fair Value: TDOC * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TDOC *?
Other financial metrics that can be useful for relative valuation.
| What is TDOC *'s n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$2.16b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | 57.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does TDOC *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6x | ||
300253 Winning Health Technology Group | 4.6x | 15.9% | CN¥14.8b |
CERT Certara | 7.7x | 8.8% | US$2.7b |
SDGR Schrödinger | 8.2x | 15.8% | US$1.8b |
GDRX GoodRx Holdings | 3.5x | 7.6% | US$2.7b |
TDOC * Teladoc Health | 0.8x | 3.6% | Mex$2.2b |
Price-To-Sales vs Peers: TDOC * is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (6x).
Price to Earnings Ratio vs Industry
How does TDOC *'s PE Ratio compare vs other companies in the Global Healthcare Services Industry?
Price-To-Sales vs Industry: TDOC * is good value based on its Price-To-Sales Ratio (0.8x) compared to the Global Healthcare Services industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is TDOC *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate TDOC *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$221.41 | Mex$295.76 +33.6% | 19.1% | Mex$425.50 | Mex$204.24 | n/a | 22 |
| Apr ’25 | Mex$251.99 | Mex$345.18 +37.0% | 17.8% | Mex$474.63 | Mex$271.21 | n/a | 22 |
| Mar ’25 | Mex$256.00 | Mex$349.29 +36.4% | 17.7% | Mex$476.52 | Mex$272.30 | n/a | 21 |
| Feb ’25 | Mex$337.00 | Mex$390.72 +15.9% | 18.7% | Mex$576.96 | Mex$271.51 | n/a | 20 |
| Jan ’25 | Mex$367.00 | Mex$392.73 +7.0% | 20.8% | Mex$585.65 | Mex$275.60 | n/a | 19 |
| Dec ’24 | Mex$325.00 | Mex$392.73 +20.8% | 20.8% | Mex$585.65 | Mex$275.60 | n/a | 19 |
| Nov ’24 | Mex$299.90 | Mex$424.36 +41.5% | 21.9% | Mex$613.01 | Mex$288.48 | n/a | 19 |
| Oct ’24 | Mex$323.00 | Mex$522.41 +61.7% | 16.1% | Mex$707.34 | Mex$353.67 | n/a | 19 |
| Sep ’24 | Mex$390.00 | Mex$514.73 +32.0% | 13.8% | Mex$683.82 | Mex$427.39 | n/a | 21 |
| Aug ’24 | Mex$466.42 | Mex$503.37 +7.9% | 14.0% | Mex$669.78 | Mex$418.61 | n/a | 21 |
| Jul ’24 | Mex$425.00 | Mex$519.91 +22.3% | 12.6% | Mex$685.22 | Mex$428.27 | n/a | 22 |
| Jun ’24 | Mex$420.00 | Mex$545.01 +29.8% | 12.5% | Mex$717.22 | Mex$448.26 | n/a | 22 |
| May ’24 | Mex$476.00 | Mex$544.87 +14.5% | 13.0% | Mex$719.20 | Mex$413.54 | Mex$221.41 | 22 |
| Apr ’24 | Mex$446.00 | Mex$556.66 +24.8% | 13.8% | Mex$740.21 | Mex$425.62 | Mex$251.99 | 21 |
| Mar ’24 | Mex$520.00 | Mex$568.73 +9.4% | 13.2% | Mex$731.94 | Mex$457.46 | Mex$256.00 | 21 |
| Feb ’24 | Mex$572.00 | Mex$604.31 +5.6% | 14.9% | Mex$844.17 | Mex$450.22 | Mex$337.00 | 22 |
| Jan ’24 | Mex$443.00 | Mex$644.73 +45.5% | 14.6% | Mex$883.76 | Mex$471.34 | Mex$367.00 | 24 |
| Dec ’23 | Mex$515.00 | Mex$633.85 +23.1% | 14.6% | Mex$865.55 | Mex$461.63 | Mex$325.00 | 24 |
| Nov ’23 | Mex$571.11 | Mex$651.50 +14.1% | 14.6% | Mex$887.40 | Mex$473.28 | Mex$299.90 | 24 |
| Oct ’23 | Mex$572.62 | Mex$725.96 +26.8% | 16.8% | Mex$1,106.77 | Mex$503.08 | Mex$323.00 | 25 |
| Sep ’23 | Mex$605.00 | Mex$754.36 +24.7% | 22.4% | Mex$1,309.16 | Mex$503.52 | Mex$390.00 | 24 |
| Aug ’23 | Mex$751.01 | Mex$858.01 +14.2% | 34.7% | Mex$1,976.27 | Mex$570.47 | Mex$466.42 | 23 |
| Jul ’23 | Mex$650.00 | Mex$923.08 +42.0% | 31.4% | Mex$1,952.51 | Mex$603.87 | Mex$425.00 | 24 |
| Jun ’23 | Mex$700.00 | Mex$1,047.02 +49.6% | 46.4% | Mex$2,796.03 | Mex$594.90 | Mex$420.00 | 25 |
| May ’23 | Mex$688.00 | Mex$1,105.21 +60.6% | 47.2% | Mex$2,877.63 | Mex$510.22 | Mex$476.00 | 26 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.